Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WGT Gains EMI Filtering Technology For OEM Sales Through Maxwell’s Sierra

This article was originally published in The Gray Sheet

Executive Summary

Wilson Greatbatch Technologies is adding electromagnetic interference (EMI) filtering technology to its implantable device component supply business through the acquisition of Maxwell Technologies' Sierra medical electronics unit

You may also be interested in...



American Home Products

Use of rhBMP-2 bone morphogenic protein product for long-bone fractures is expected by the firm's Genetics Institute unit to go before FDA's Orthopedics and Rehabilitation Devices Advisory Panel by the end of 2002. The firm received a not-approvable letter for the indication June 22 due to problems with the initial clinical trial design and data interpretation (1"The Gray Sheet" June 25, 2001, p. 27). Stryker's OP-1 will be the first bone morphogenic protein product on the market following humanitarian device exemption clearance for long-bone non-union fractures, announced Oct. 17 (2"The Gray Sheet" Oct. 22, 2001, p. 20). AHP hopes to be on the market in early 2003

American Home Products

Use of rhBMP-2 bone morphogenic protein product for long-bone fractures is expected by the firm's Genetics Institute unit to go before FDA's Orthopedics and Rehabilitation Devices Advisory Panel by the end of 2002. The firm received a not-approvable letter for the indication June 22 due to problems with the initial clinical trial design and data interpretation (1"The Gray Sheet" June 25, 2001, p. 27). Stryker's OP-1 will be the first bone morphogenic protein product on the market following humanitarian device exemption clearance for long-bone non-union fractures, announced Oct. 17 (2"The Gray Sheet" Oct. 22, 2001, p. 20). AHP hopes to be on the market in early 2003

Sulzer Biologics Ne-Osteo U.S. Fusion Filing Awaits Marketing Agreement

Sulzer Biologics says it will find a U.S. distribution partner for the Ne-Osteo Spine bone morphogenic protein prior to pursuing FDA approval for use in spinal fusion.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel